Investing.comDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 19:36:32·⟳ 抓取 19:38:33 +2m01s·⚡ 决策 10-26 19:45:20 +6m47s·1.3 天前
Immuneering在ESMO展示三期MAPKeeper 301胰腺癌试验设计，无新增临床数据（同催化已处理，Investing.com转载）
同一具体催化（ESMO 2026 MAPKeeper 301 TiP海报）已在13分钟前由通稿（wire）和公司IR页两条源处理并判不做；本条Investing.com文章系AI生成的二次转载，事实集完全相同，无金额、数据读出、监管推进或官方新表态等任何增量。
📄 原文Investing.com↗ 原文
Immuneering presents phase 3 pancreatic cancer trial design
Five things to watch in markets in the week ahead NEW YORK - Immuneering Corporation (NASDAQ:IMRX) presented a poster F…
不做 Immuneering Corporation（IMRX.US）
重复消息：ESMO 2026 MAPKeeper 301三期试验设计TiP海报已在13分钟前由通稿和公司IR两源处理并判不做；Investing.com本条为AI生成转载，无新增临床数据、无监管或合作增量、无近期读出，无预期差（NO_INCREMENTAL_FACT）；亦无做空依据。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ESMO海报只介绍三期试验设计，无新临床数据；17.3个月OS等为6月ASCO已公开的二期a旧数据，三期6月已启动。同催化13分钟前已由通稿和IR页处理，本条仅Investing.com转载，无预期差，不做。
🔎 新鲜度:最早出现 2026-10-25 · 扩散 high · price-in 风险 high ↗
主要风险
- 三期仍在招募、OS数据读出尚远，期间股价由其他催化（融资、合作、其他管线）驱动，本条不提供方向性edge
先例如何影响了这次决策
对本次决策的影响:未改变结论：维持不做
方向:无增量的TiP设计海报不适用事件先例研究；同催化已被处理，重复消息不再展开先例
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 325 ms
{"result": "search_processed_events:agent query=`immuneering atebimetinib phase 3 pancreatic cancer mapkeeper 301 trial design esmo poster | imrx atebimetinib metastatic pancreatic adenocarcinoma nct07562152`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 69.5/72 小时、2870 条本臂决策(完整)，返回 2 条候选。\n• 10-26 11:31 UTC(北京 19:31) [
原文全文
展开原文 · 2,109 字
Five things to watch in markets in the week ahead
NEW YORK - Immuneering Corporation (NASDAQ:IMRX) presented a poster Friday describing the design of its ongoing Phase 3 clinical trial evaluating atebimetinib in combination with modified chemotherapy for first-line metastatic pancreatic cancer at the European Society for Medical Oncology Congress in Madrid, according to a press release statement.
The MAPKeeper 301 trial is a global, randomized, open-label study comparing atebimetinib combined with modified gemcitabine and nab-paclitaxel against standard-of-care gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. The primary endpoint is overall survival.
Patients are randomized 1:1 to receive either atebimetinib 320 mg orally once daily with modified chemotherapy administered on days 1 and 15 of each 28-day cycle, or standard-of-care chemotherapy administered weekly for three consecutive weeks followed by one week off. Randomization is stratified by geography, presence of liver metastases, performance status, and whether metastatic disease is newly diagnosed or recurrent.
The trial builds on Phase 2a results presented at the American Society of Clinical Oncology meeting in June, which showed median overall survival of 17.3 months, median progression-free survival of 8.3 months, an objective response rate of 36%, and a disease control rate of 82% among 55 patients. The company noted these results were not from a head-to-head comparison with standard treatment.
Secondary endpoints include progression-free survival, overall response rate, disease control rate, safety, and quality of life. Eligible patients must have confirmed metastatic pancreatic adenocarcinoma, measurable disease, and an Eastern Cooperative Oncology Group performance status of 0 or 1.
The study began dosing patients in June and is currently recruiting. Additional information is available at ClinicalTrials.gov under identifier NCT07562152.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEW YORK - Immuneering Corporation (NASDAQ:IMRX) presented a poster Friday describing the design of its ongoing Phase 3 clinical trial evaluating atebimetinib in combination with modified chemotherapy for first-line metastatic pancreatic cancer at the European Society for Medical Oncology Congress in Madrid, according to a press release statement.
The MAPKeeper 301 trial is a global, randomized, open-label study comparing atebimetinib combined with modified gemcitabine and nab-paclitaxel against standard-of-care gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. The primary endpoint is overall survival.
Patients are randomized 1:1 to receive either atebimetinib 320 mg orally once daily with modified chemotherapy administered on days 1 and 15 of each 28-day cycle, or standard-of-care chemotherapy administered weekly for three consecutive weeks followed by one week off. Randomization is stratified by geography, presence of liver metastases, performance status, and whether metastatic disease is newly diagnosed or recurrent.
The trial builds on Phase 2a results presented at the American Society of Clinical Oncology meeting in June, which showed median overall survival of 17.3 months, median progression-free survival of 8.3 months, an objective response rate of 36%, and a disease control rate of 82% among 55 patients. The company noted these results were not from a head-to-head comparison with standard treatment.
Secondary endpoints include progression-free survival, overall response rate, disease control rate, safety, and quality of life. Eligible patients must have confirmed metastatic pancreatic adenocarcinoma, measurable disease, and an Eastern Cooperative Oncology Group performance status of 0 or 1.
The study began dosing patients in June and is currently recruiting. Additional information is available at ClinicalTrials.gov under identifier NCT07562152.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
fbacbfadd0· 2026-10-26 19:45 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前